64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer

64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Mixed Adenocarcinoma of the Stomach; Recurrent Gastric Cancer; Stage IA Gastric Cancer; Stage IB Gastric Cancer; Stage IIA Gastric Cancer; Stage IIB Gastric Cancer; Stage IIIA Gastric Cancer; Stage IIIB Gastric Cancer; Stage IIIC Gastric Cancer; Stage IV Gastric Cancer

Interventions: Radiation: copper Cu 64-DOTA-trastuzumab; Device: positron emission tomography; Other: laboratory biomarker analysis; Procedure: Computed Tomography

Sponsors: City of Hope Medical Center

Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 17, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments